Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:25 2024-05-10 am EDT			After market 03:40:34 pm
28.67 ^EUR	+2.28%		28.61	-0.21%

05:32pm	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
09:46am	FRESENIUS : Preparing for a strong(er) future performance

FRESENIUS SE : Deutsche Bank reiterates its Neutral rating

August 05, 2022 at 04:32 am EDT

Falko Friedrichs from Deutsche Bank retains his Neutral opinion on the stock. The target price is reduced from EUR 36 to EUR 28.

Latest news about Fresenius SE & Co. KGaA

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	11:32am	MT
FRESENIUS : Preparing for a strong(er) future performance	03:46am
FRESENIUS SE : Deutsche Bank keeps its Buy rating	May. 09	ZD
Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup	May. 08	DJ
Home REIT cuts borrowings, Genflow shares restored	May. 08	AN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Fresenius becomes more optimistic thanks to subsidiary Kabi - exit from Vamed	May. 08	DP
UBS rates Fresenius SE as 'Buy' - Target 34 euros	May. 08	DP
Dpa-AFX Overview: COMPANIES from 08.05.2024 - 15:15	May. 08	DP
FRESENIUS SE : Berenberg reiterates its Buy rating	May. 08	ZD
FRESENIUS SE : Buy rating from UBS	May. 08	ZD
FRESENIUS SE : Warburg Research reaffirms its Buy rating	May. 08	ZD
FRESENIUS SE : Barclays maintains a Buy rating	May. 08	ZD
Transcript : Fresenius SE & Co. KGaA, Q1 2024 Earnings Call, May 08, 2024	May. 08
FRESENIUS SE : Gets a Neutral rating from JP Morgan	May. 08	ZD
FRESENIUS SE : Jefferies gives a Buy rating	May. 08	ZD
European Midday Briefing : Stocks Buoyed by Some Solid Earnings	May. 08	DJ
Fresenius makes strong start to the year - forecast raised thanks to subsidiary Kabi	May. 08	DP
Fresenius Medical beats earnings expectations, keeps outlook; shares sink	May. 08	RE
German healthcare group Fresenius Q1 EBIT beats expectations	May. 08	RE
Strabag, Porr to Buy Portions of Fresenius' Vamed Group	May. 08	MT
Fresenius Hikes FY24 Outlook	May. 08	MT
EMEA Morning Briefing : Stock Futures Mixed as Earnings in Focus	May. 08	DJ
Fresenius SE & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
PORR AG and Strabag SE signed a purchase agreement to acquire Vamed Engineering Gmbh from Fresenius SE & Co. KGaA for ?90 million.	May. 07	CI

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-17 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : Preparing for a strong(er) future performance

May 10, 2024 at 03:46 am EDT

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.03 EUR

Average target price

36.28 EUR

Spread / Average Target

+29.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	+2.14%	17.01B
HCA HEALTHCARE, INC.	+20.62%	84.31B
CVS HEALTH CORPORATION	-29.20%	69.9B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.06B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.88%	17.38B
QUEST DIAGNOSTICS INCORPORATED	+0.54%	15.35B
REDE D'OR SÃO LUIZ S.A.	+6.95%	12.91B
TENET HEALTHCARE CORPORATION	+68.59%	12.47B
FRESENIUS MEDICAL CARE AG	+6.43%	12.26B
DAVITA INC.	+31.65%	12.1B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Deutsche Bank reiterates its Neutral rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services